These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10028721)

  • 1. [A study of clinical significance of leucocyte migration test in drug eruption].
    Abe M; Uno K
    Arerugi; 1998 Dec; 47(12):1264-72. PubMed ID: 10028721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on the pathogenic mechanism of beta-lactam hypersensitivity by the detection of leucocyte migration activating factor and leucocyte migration inhibitory factor].
    Uno K
    Arerugi; 1990 Dec; 39(12):1605-11. PubMed ID: 2096806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A study of clinical significance of leukocyte migration inhibition test in drug-induced hypersensitivity pneumonitis].
    Uno K; Kondo A
    Arerugi; 1995 Dec; 44(12):1401-9. PubMed ID: 8871295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on the pathogenic mechanism of hypersensitivity to antibacterial agents--correlations of leucocyte migration activating factor and leucocyte migration inhibitory factor with interleukin-2 and interferon-gamma].
    Uno K
    Arerugi; 1993 May; 42(5):656-64. PubMed ID: 8323465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlations of leucocyte migration activating factor with interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor-alpha in drug allergy].
    Sano N; Uno K
    Arerugi; 1998 Nov; 47(11):1198-204. PubMed ID: 9893337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on the pathogenic mechanism of beta-lactam hypersensitivity by the detection of leucocyte migration activating factor and leucocyte migration inhibitory factor--structural correlations with allergic symptoms due to beta-lactam antibiotics].
    Uno K
    Arerugi; 1992 Mar; 41(3):418-27. PubMed ID: 1575639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage migration inhibition factor (MIF) in drug eruption.
    Halevy S; Grunwald MH; Sandbank M; Buimovice B; Joshua H; Livni E
    Arch Dermatol; 1990 Jan; 126(1):48-51. PubMed ID: 2136987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Macrophage migration inhibition factor as a diagnostic aid in drug eruptions].
    Halevy S; Grunwald MH; Sandbank M; Buimovice B; Livni E
    Harefuah; 1991 Sep; 121(5-6):147-9. PubMed ID: 1834535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of elevated interleukin-8 (CXCL8) and detection of leukocyte migration inhibitory activity in patients allergic to beta-lactam antibiotics.
    Abe M; Yagi M; Wakasugi Y; Hattori H; Uno K
    Allergol Int; 2011 Dec; 60(4):497-504. PubMed ID: 21778813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized pustular drug eruptions: confirmation by in vitro tests.
    Lazarov A; Livni E; Halevy S
    J Eur Acad Dermatol Venereol; 1998 Jan; 10(1):36-41. PubMed ID: 9552755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in vitro drug-induced interferon-gamma release.
    Halevy S; Grossman N
    Isr Med Assoc J; 2008 Dec; 10(12):865-8. PubMed ID: 19160944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of leucocyte migration tests to detection of allergenic drugs in patients with hypersensitivity to beta-lactam antibiotics.
    Uno K; Yamasaku F
    J Antimicrob Chemother; 1989 Aug; 24(2):241-50. PubMed ID: 2793647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous release of leukocyte migration inhibition factor (LMIF) by lymphocytes in chronic lymphatic leukemia patients.
    Crivii SM; Crişan M; Crişan M
    Arch Geschwulstforsch; 1984; 54(1):85-9. PubMed ID: 6367694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of skin testing in cutaneous drug eruptions in routine practice.
    Tchen T; Reguiaï Z; Vitry F; Arnoult E; Grange A; Florent G; Bernard P
    Contact Dermatitis; 2009 Sep; 61(3):138-44. PubMed ID: 19780771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug eruptions: the value of oral rechallenge test and patch test.
    Puavilai S; Chunharas A; Kamtavee S; Pongwiriyapanich S
    J Med Assoc Thai; 2002 Feb; 85(2):263-9. PubMed ID: 12081129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period.
    Lammintausta K; Kortekangas-Savolainen O
    Acta Derm Venereol; 2005; 85(6):491-6. PubMed ID: 16396795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical spectrum of drug rashes due to antiepileptics.
    Sharma VK; Vatve M; Sawhney IM; Kumar B
    J Assoc Physicians India; 1998 Jul; 46(7):595-7. PubMed ID: 12152838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Leukocyte migration inhibition test in drug-induced pneumonitis].
    Suzuki K; Rahman SG; Akoun GM
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Jan; 30(1):76-81. PubMed ID: 1625399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed drug eruption from piroxicam.
    Cuerda Galindo E; Goday Buján JJ; García Silva JM; Martínez W; Verea Hernando M; Fonseca E
    J Eur Acad Dermatol Venereol; 2004 Sep; 18(5):586-7. PubMed ID: 15324401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.